| Previous Close | 12.10 |
| Open | 12.10 |
| Bid | 12.87 x 300 |
| Ask | 13.87 x 1000 |
| Day's Range | 11.83 - 13.98 |
| 52 Week Range | 3.82 - 16.94 |
| Volume | 3,355,237 |
| Avg. Volume | 2,547,704 |
| Market Cap | 427.86M |
| Beta | 3.36 |
| PE Ratio (TTM) | -9.29 |
| EPS (TTM) | -1.44 |
| Earnings Date | Aug 2, 2017 - Aug 7, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
- Business Wire•14 days ago
GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
GlycoMimetics, Inc. announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc., to its Board of Directors.
- Accesswire•19 days ago
Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics
NEW YORK, NY / ACCESSWIRE / June 7, 2017 / U.S. markets fell for the second consecutive day on geopolitical concerns. Inventors appear to be cautious ahead of upcoming events such as the U.K. general election, ...
- Business Wire•21 days ago
GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2017 Global Healthcare Conference in New York City, on Wednesday, June 7, 2017, at 2:00 p.m.